Havrix Adult

Havrix Adult is a viral vaccine containing hepatitis A virus (inactivated) adsorbed on aluminium hydroxide, supplied as an injectable solution. The product is manufactured for the EU market and is administered by intramuscular or subcutaneous injection. It is intended for adult individuals to provide active immunization against hepatitis A infection, stimulating the body’s immune response and the production of protective antibodies in the bloodstream of the vaccinated person.

Havrix Adult is indicated for the prevention of hepatitis A infection in adults.

- Primary prophylaxis for hepatitis A in healthy adults. - Post‑exposure prophylaxis for individuals who have been exposed to hepatitis A virus. - Immunization of travelers to regions where hepatitis A is endemic. - Vaccination of individuals with chronic liver disease to reduce risk of severe hepatitis A. - Use in outbreak settings to control spread of hepatitis A.

The safety profile of Havrix Adult includes both common, generally mild reactions and rare, potentially serious events.

Common: - Pain, redness, or swelling at the injection site, usually resolving within a few days. - Low‑grade fever lasting 24‑48 hours. - Headache or fatigue that is mild and transient. - Mild muscle aches affecting the arm or shoulder. - Nausea or mild gastrointestinal upset occurring shortly after vaccination. - Temporary joint pain that subsides without treatment.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, hives, or swelling of the face and throat. - Guillain‑Barré syndrome, a rare neurological disorder that may develop weeks after vaccination. - High fever or seizures, which are very uncommon but require medical attention. - Thrombocytopenia, an extremely rare drop in platelet count that can cause easy bruising. - Autoimmune hepatitis, an extremely rare inflammation of the liver observed in isolated cases.

Before administering Havrix Adult, healthcare providers should evaluate several precautionary factors to ensure safe use.

- Known severe allergy to any vaccine component, especially aluminium hydroxide. - History of severe allergic reaction (anaphylaxis) to a previous dose of hepatitis A vaccine. - Acute moderate or severe illness at the time of vaccination; defer until recovery. - Immunocompromised individuals may have a reduced antibody response; vaccination is still recommended but efficacy may be lower. - Pregnant or breastfeeding women should discuss potential benefits and risks with a clinician. - Individuals with chronic liver disease should be vaccinated, but monitor for any adverse events. - Persons with a bleeding disorder should receive the injection using proper technique to minimize hematoma.

Havrix Adult may interact with certain medications or biologics; awareness of these interactions helps guide safe administration.

Avoid: - Simultaneous administration with other live vaccines (e.g., measles, mumps, rubella) is generally avoided; separate by at least 4 weeks. - Use of immunoglobulin or blood products within 2 weeks before or after vaccination may reduce vaccine efficacy.

Use with caution: - Antiviral therapy for hepatitis B or C may alter immune response; monitor antibody levels. - Immunosuppressive drugs (e.g., corticosteroids, biologics) may diminish antibody production; consider timing. - Pregnancy and lactation: no specific contraindication, but discuss risk/benefit with provider. - Chronic kidney disease: no dose adjustment needed, but monitor for adverse reactions.